Fresenius Medical Care CFO Takes Over as CEO

Fresenius Medical Care has appointed Helen Giza—previously deputy CEO of the company—as its new CEO. She succeeds Dr. Carla Kriwet, who will leave the company at her own request and by mutual agreement due to strategic differences, according to the company.
 
Giza will also continue serve as CFO of Fresenius Medical Care until a successor is appointed.
 
“In a fundamentally sound industry Fresenius Medical Care now needs to sharpen its focus on the operational turnaround, further drive performance improvements, and focus on its core,” Michael Sen, Chairman of the Fresenius Medical Care Management AG Supervisory Board and CEO of Fresenius, told the press. “We are delighted that Helen Giza will take over as CEO. She is ideally suited to lead Fresenius Medical Care for what lies ahead. During her tenure with the company, Helen Giza has gained thorough expertise in renal healthcare and has a deep understanding of the company. I am very much looking forward to continuing working with Helen Giza in her new role. On behalf of the Supervisory Board, I would like to thank Carla Kriwet, and we wish her all the best for the future.”
 
Helen Giza said: “I am honored by the appointment and trust the Supervisory Board has placed in me. The role comes with significant responsibility towards the patients we serve. With the knowledge gained as CFO and Chief Transformation Officer of the company, I feel well placed to sharpen the focus on operational turnaround. I truly believe in Fresenius Medical Care’s mission, its passionate employees and great potential.”
 
Carla Kriwet said: “In this short time, I have met a fascinating company with a very positive corporate culture that works every day to make patients’ lives more worth living. The company has great growth potential and is about to undergo a major transformation. I thank my whole team for the great support and wish the company all the best!”
 
Giza joined Fresenius Medical Care in 2019 as CFO and took on the roles of deputy CEO and chief transformation officer in 2022. She was previously chief integration and divestiture management officer at Takeda Pharmaceuticals since 2018. Before that she was CFO of Takeda’s U.S. business unit since 2008. And prior to that, she held international and finance controlling positions, among others, at TAP Pharmaceuticals and Abbott Labs.